

An Appraisal of Nephroprotection and the Scope of Natural Products in Combating Renal Disorders

Qazi Zaid Ahmad^{1*}, Nasreen Jahan², Ghufra Ahmad³ and Tajuddin¹

¹Department of Saidla, Faculty of Unani Medicine, AMU, Aligarh, India

²Department of Ilmul Advia, Faculty of Unani Medicine, AMU, Aligarh, India

³National Institute of Unani Medicine, Bangalore, India

*Corresponding author: Qazi Zaid Ahmad, Department of Saidla, Faculty of Unani Medicine AMU, Aligarh, India, Tel: +919897775146; E-mail: Zaidnium@gmail.com

Rec date: Feb 13, 2014, Acc date: May 27, 2014, Pub date: May 31, 2014

Copyright: © 2014 Ahmad QZ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Although the concept of nephroprotection is relatively new but evidences are accumulating to demonstrate that the drugs described to be useful in various renal disorders because of their nephroprotective and nephrotonic effect as described in Unani or other traditional medicines, have diverse therapeutic uses and can be used to manage many renal diseases and their complications or at least to arrest their progression. The traditional systems of medicines would offer some novel drugs, which may be effective in different pathological conditions of the kidney. The drugs of traditional systems of medicines are frequently used to protect the renal function and to delay the progression of renal diseases to CKD and ESRD. In recent past it has been shown that a number of drugs from herbal medicine possess promising nephroprotective effect. The researchers are keen to develop an effective, safe and low cost drug from alternative medicine. However, the drugs identified to be effective in renal diseases on the basis of age-old practices of traditional medicines and few scientific studies need to be evaluated for their pharmacological profile and wide therapeutic potential. This paper gives a detailed account of the traditional drugs useful in renal diseases and the scientific studies conducted so far to validate them.

Keywords: Nephroprotection; Traditional medicine; Ayurveda; Unani; Nephroprotective herbs

Introduction

Nephroprotection has known ample development lately and consists in the measures which protect the kidney against many aggressive factors. The concept of nephroprotection in modern medicine is relatively new and can hardly be traced before eighties. The complex nature of renal diseases and their progression to renal failure (both acute and chronic) and end stage renal disease (ESRD) makes its management quite difficult. The majority of cases of renal disease remain unnoticed unless they progress to advance stages when the conventional therapeutic interventions are usually not sufficient to cure them completely. But the major problem with kidney disease is its progression to a stage when virtually no option works at all except the renal replacement therapy (RRT).

Two major components of RRT viz. dialysis and kidney transplantation are highly sophisticated and thereby too costly to be affordable for an average income group. Only small chunk of the elite class can take the luxury of such a regimen subject to the availability of this facility in reach. That is why most of the patients of kidney disease are left to die mainly in developing and poor countries because of non-availability of RRT facilities in their region or their inability to pay for it. Globally, it has been estimated that by 2010 over 2 million individuals has been treated by RRT at a cost of \$1 trillion [1]. More than 100 countries worldwide do not have any provision for RRT [2] and consequently, more than a million individuals can be assumed to die every year from ESRD. About 100 countries have been identified that possess no such facility at all [3]. Availability of kidneys for

transplantation is another important problem consistent with RRT. Although, expenditure on RRT is costing about 1 trillion dollar but the substantial percentage of patients in need of it, still remains untreated and consequently has out-numbered those receiving the treatment. In 1990 it was 3.78 million and is expected to become 7.63 million in 2020 [4]. The alarming increase in the prevalence of CKD that progresses to end stage renal disease requiring renal replacement therapy, demands huge fund allocation [5]. In addition, individuals with kidney diseases are at an increasing risk of other systemic diseases which frequently proves to be fatal [6]. At the end of 2004, 1783000 patients worldwide were receiving treatment for ESRD, of which 77% were on dialysis and 23% had functioning renal transplant, and this number is increasing at the rate of 7% every year.

In nut shell therefore it can be said that it is almost next to impossible to provide replacement therapy to all patients requiring it. The next option left with the physicians is to think of alternatives and the best way to come out of such a situation or at least scale down the prevalence and consequently the financial burden to a significant level, is to protect the kidney function, slow the progression of disease and delay the need of RRT. This second option actually paved the way for envisaging a concept that is broadly termed as nephroprotection [7,8].

The skyrocketing cost of CKD and ESRD management in developed countries due to the relentlessly increasing number of patients who have outnumbered the patients maintained at RRT, and availability of very limited facilities in poor countries almost ensured that RRT cannot be provided to all in need of it. This forced the physicians to think to adopt some alternate measures to preserve the renal function as long as possible and slow the renal disease progression with an aim

to protect the kidney and delay the need of RRT to the maximum possible extent.

After the experimental demonstration that ACE inhibitors slow the progression of loss of renal function in a number of models of renal diseases [7,8]. It was for the first time conceived that a treatment strategy can be devised aiming at preserving renal function instead of providing some supportive and passive therapy to the patients of kidney diseases. The concept of renoprotection/nephroprotection thus emerged and strongly stimulated the clinicians to apply this concept into practice aiming at early detection and subsequent prevention of progression of kidney disease, mainly through lifestyle adjustment and the use of new pharmacological agents [3]. The nephroprotection thus includes:

- Preservation of renal function as long as possible.
- Treating the kidney disease at the onset/primary stage.
- Slowing the progression of kidney disease.
- Delaying the need of RRT to maximum possible extent.

The pathology of renal disease that compromises its functional ability and the structural integrity has been described to arise mainly through following mechanisms:

Impairment of lysosomal function which in turn causes decrease in the density and height of the brush border microvilli, dilation of the cisternae of rough endoplasmic reticulum and cytoplasmic vacuolization of the tubular epithelium. As injury progresses, mitochondrial swelling, tubular necrosis and desquamation occur.

Oxidative stress in which chemicals may produce membrane damage and cell death.

Disturbance in intracellular Ca²⁺ homeostasis and sustained increase in cytosolic Ca²⁺ which causes cell death by the disruption of the plasma membrane, cytoskeleton, endoplasmic reticulum and mitochondria.

Chemical may also induce cell death through an initial DNA damage or by apoptosis.

Several chemicals (both therapeutic and non-therapeutic) have toxic effects on one or more anatomical elements of the kidney. Toxic effects may be acute or chronic, and they may be direct or mediate indirectly through immunological mechanisms. The health impact of nephrotoxic chemicals is related to risk factors, which include the intergrade of the renal functional reserve and factors such as pre-existing renal damage, disease, age, sex, and diet. Irrespective of the mechanism however, the toxicant set into motion a number of physio-chemical processes that initiate a series of degenerative changes and alter the morphology and the functions of the kidney [9-11]. A drug that can ameliorate one of the mechanisms or processes mentioned above can be used as an important nephroprotective agent because such an agent will help in the restoration of kidney function and improvement in the structural impairment of the kidney and thereby slowing its progression. The mechanisms discussed above cannot be said however to be exclusively responsible for nephrotoxicity, because several other intricacies and complex processes have been described to be associated with the normalization of kidney functions which directly or indirectly influence the hemodynamics of kidney. Similarly, some related pharmacological effects such as diuretic and anti-inflammatory etc. have also been shown to complement the nephroprotection [12]. Few drugs in recent years have been found to

possess significant nephroprotective effect notwithstanding that their mechanism was not fully elucidated [13]. Still, they satisfied the criteria of nephroprotection owing to their overall efficacy on renal function [7].

In modern medicine ACE inhibitors and ARBs are mainly used to induce renoprotection, however these agents are neither the drugs of choice for this purpose nor can be used exclusively to produce renoprotective effects, rather they are mainly effective in nephropathies associated with blood pressure and diabetes etc [13]. Thus, by treating a patient with the above mentioned drugs it is obligatory to induce a pharmacological effect that may not be necessarily needed by him. The associated toxicities of these agents also limit their use to a great extent. Although, ARBs are comparatively safer than ACE inhibitors but some of the side effects are common to both such as neutropenia, proteinuria, angioneurotic edema, hyperkalemia especially in patients with renal impairment etc. [13], which undermine the therapeutic utility of these agents. A drug categorized to be effective specifically as a nephroprotective agent without having liability to produce some serious side effects will be the obvious choice for the patients suffering from renal dysfunction or failure.

Medicinal plants are a source for a wide variety of natural antioxidants and are used for the treatment of diseases throughout the world [14]. Some of these properties are antimicrobial [15], anti-cancer [16], anti-diabetic [17], anti-atherosclerosis [18], immunomodulatory [19], and even reno-protection or hepato-protective effects [20].

It is being appreciated that traditional systems of medicine can offer some effective drugs from their treatise to be useful in diverse pathological conditions of kidney and thus can be used to protect the renal function and prevent/slow the progression of renal diseases to CKD or ESRD. A number of drugs from herbal sources have been shown to possess promising nephroprotective and related effects in some recent studies and researchers are making it a point to concentrate seriously on the development of nephroprotective agents from traditional sources [21,22].

Recently, attentions are mostly on protection or prevention as well as accelerating the regeneration of tubular cells against injurious insults to the kidney [23,24].

Keeping in view of above, Scientists are focusing to develop herbal nephroprotective agents from the plants source which possess antioxidant properties for the prevention and cure of renal disorders as in most of the cases it was found that the oxidative stress are the common factor with other associated cause resulting renal tubular necrosis [23]. So it can be assumed that plants which have antioxidant activities due to phytochemicals including phenolic and carotenoid compounds can reduce the risk of several chronic and degenerative complications [25,26].

Traditional System of Indian Medicine including Ayurveda, Unani etc. are also not wanting in offering drugs for numerous kidney diseases. It claims to possess a number of drugs that can be used successfully in the treatment of renal diseases [21,22]. Some of the drugs mentioned in Ayurveda and Unani literature and being practiced by physicians, have been demonstrated to produce some important effects such as diuretic, anti-inflammatory, antioxidant & nephroprotective effect against known toxicants. Recently some important drugs of Unani Medicine such as Bisehri Booti (*Aerva lanata*, Juss) [27], Revand Chini (*Rheum officinalis*) [28,29], Haleela

(*Terminalia chebula*) [30], *Zanjabeel* (*Zingiber officinale*) [31], *Asgand* (*Withania somnifera*) [32], *Khare khasak* (*Tribulus terrestris*) [33], *Banadequl Buzoor* (a poly herbal formulation) [34], and *Jawarish Zarooni Sada* (a poly herbal formulation) [21] have been investigated for their diuretic, nephroprotective and associated effects they have shown promising nephroprotective effect. *Quercetin* isolated from vegetable sources has been shown to produce nephroprotective effect against cisplatin induced nephrotoxicity [35]. *Cordyceps sinenses* has been shown to produce protective effect against gentamicin and kanamycin induced nephrotoxicity [36]. Leaf extract of *Clerodendron trichotomum*, has been reported to possess diuretic, natriuretic and kaliuretic activity [37]. Similarly, *curcumin* isolated from turmeric has been reported to produce protective effect against adriamycin induced nephrotoxicity [38].

Plant as Nephroprotective Agents

Ginger which was studied for its nephroprotective effect significantly protected the renal cells and reduced the severity of tubular damage caused by gentamicin and also showed the tubular regeneration potential in animal models [39]. Another study in which pomegranate seed oil is evaluated for its nephroprotective activity the findings clearly showed attenuation of Diazinon -induced nephrotoxicity via; a) improving kidney function by reducing urinary glucose; b) reducing serum urea and creatinine; and c) decreasing MDA concentration [40]. The co-administration or post administration of garlic juice found to be effective in gentamicin induced acute kidney failure [41].

A polyherbal formulation was studied for its protective effect on mice administered with 3 mg/kg of Cisplatin. Among the ingredients of the formulation *Angelica radix* was more effective and it showed strongest protective effect against the toxicity, the effectiveness of *Angelica radix* was found to be due to its constituent L-malate which was isolated and tested for nephroprotective activity [42].

The simultaneous administration of the plant *Cordyceps sinensis* with gentamicin protects the proximal tubular cells from gentamicin toxicity [36]. Results are reported on the clinical, experimental and immunological studies on *Biskhapra* (*Boerhavia diffusa*) the observations reveal equivalent diuretic effect of frusemide, *Biskhapra* (*Boerhavia diffusa*) increases serum protein level and decreases urinary protein excretion in patients of nephritic syndrome. Clinically *Biskhapra* was proved to be useful and safe drug in patients of nephritic syndrome [43]. Simultaneous administration of *Gokhroo* (*Tribulus terrestris*) 200 mg/kg/day/orally and gentamicin to female rats decreased the gentamicin induced nephrotoxicity in both structural and functional terms. The effects were comparable to that of *Verapamil* [33]. Methanolic extract of *Icacina tricantha* tuber was found to be effective in carbon tetra chloride induced nephrotoxicity. The rats treated only with carbon tetra chloride lost weight, but those with carbon tetra chloride and extract gained weight. Histopathological examination of the kidney revealed complete protection against carbon tetra chloride induced nephrotoxicity [44].

The hydro alcohol standardized extract of *Echinacea pallida* given to mice in association with the intraperitoneal administration of cisplatin exhibited protective effect expressed by a diminished loss and fast recovery of the animals' body weight, pretreatment with *Echinacea pallida* also decreased cisplatin nephrotoxicity estimated from the level of kidney homogenate oxygen consumption [45]. The protective effect of *Asgand* (*Withania somnifera*) on Cadmium induced toxicity in

mice kidney has been studied. Aqueous extract of 40 mg/0.1ml concentration was prepared from the dried roots of *Asgand*, Mice were fed with Cadmium chloride along with *Asgand* extract and *Asgand* extract alone (1.14 gm/kg body weight) for 20 days. Results based on lipid peroxidation indicate that *Asgand* is capable of reducing toxicity caused by cadmium [46].

A Unani formulation "*Banadequl Buzoor*" was tested for nephroprotective activity. The formulation was found to decrease the serum urea and serum creatinine levels significantly [23]. Effects of *Geranin* tannin extracted from the herb *Geranium humbergii* on *Puromycin* Amino nucleoside nephrosis were studied in rats. The urine protein excretion in female rats (140-160 gm) receiving *puromycin* amino nucleoside on 7th day, reached its maximum after injection of *puromycin* amino nucleoside injection on 14th day, but in animals treated intramuscularly with *geranin* 10 mg/kg body weight the urinary protein was reduced approximately 35%. The increase in serum cholesterol and lipid peroxide produced by *puromycin* amino nucleoside were also suppressed by *geranin*, observation by electron microscopy revealed that the degree of abnormality in glomerular epithelial cells was lower in rats treated with *geranin* after the *puromycin* amino nucleoside injection than in the rats treated with the *puromycin* amino nucleoside alone [47]. A Unani formulation "*Jawarish Zarooni Sada*" has been reported to possess nephroprotective activity [21]. A Unani drug *Kabab chini* (*Piper cubeba*) was investigated for nephroprotective activity in chemically induced nephrotoxicity showed significant nephroprotective effect against gentamicin and cisplatin nephrotoxicity [48,49]. Another study demonstrated that *Khurfa* (*Portulaca oleracea* Linn.) possesses significant nephroprotective effect against gentamicin and *doxorubicin* induced nephrotoxicity [50].

Milk thistle (*Silybum marianum*) seeds containing several potent antioxidant flavonolignans collectively called *silymarin* have both hepatic and renal protective effects in rodent models [51]. The main constituents composing *silymarin* are *silibinin*, *silicristin*, *isosilibinin*, and *silidianin*. *Silibinin* and *silicristin*, aside from their antioxidant effects against damaging free radicals, also stimulate RNA and protein synthesis which is important for renal and hepatic repair mechanisms. In addition these same flavonolignans protect kidney cells in culture from the renal toxic effects of the drugs *paracetamol*, *cisplatin*, and *vincristine* [52]. Another study in rats demonstrated that *silibinin* protected renal tubular cells from the oxidative damage from *cisplatin* [53]. *Silibinin* also protects against experimental *cyclosporine* nephrotoxicity [54].

Another potentially useful nephro-protective medicinal herb popular in Ayurvedic medicine is *picroliv* (*Picrorhiza kurrooa*). Extracts from the roots and rhizomes offer protection against various hepatic and renal toxins. *Picroliv* protects the kidney in a renal ischemia-reperfusion induced injury (IRI) model in rats [55]. Pretreatment of rats orally with *picroliv* for 7 days before initiation of experimental IRI lowered renal lipid peroxidation, reduced apoptosis, and generally increased the viability of renal cells. Another study in rats found that oral administration of *picroliv* to rats exposed to the carcinogen 1,2-dimethylhydrazine decreased the extent of renal necrosis [56]. As with *milk thistle* animal studies using *picroliv* support their potential clinical benefit as nephro-protectants. However, human clinical studies are needed to confirm these Results in cell culture and animal models.

Astragalus (*Astragalus membranaceus*), a popular herb used in Chinese traditional medicine, is effective against experimentally

induced glomerulonephritis in rats, especially in reducing proteinuria [57]. Several clinical studies also showed a reduction in proteinuria in patients with chronic glomerulonephritis by Astragalus [58]. Cordyceps (*Cordyceps sinensis*), a fungus found growing in caterpillar larvae of certain moths, has long been valued as a kidney tonic in China [59]. One study in 61 patients with lupus nephritis showed that a combination of 2 g to 4 g of cordyceps powder together with 0.6 grams of artemisinin from the plant *Artemisia annua* for 3 years improved kidney function as measured by creatinine clearance [60]. Another study found that cordyceps lessened the nephrotoxicity of cyclosporine in kidney transplant patients [61].

The Japanese traditional remedy Sairei-to, a 12 herb mixture, has shown in human and animal studies to protect the kidney in gentamicin renal toxicity, IgA nephropathy, and lupus nephritis [62]. Another study in rats showed that extracts from the root of the plant *Salvia miltiorrhiza* (Danshen) along with fructose 1,6-diphosphate prevented the decline of renal cortical Na-K-ATPase activity induced by ischemia and gentamicin [63]. Further, extracts of the plant *Herniaria hirsute* inhibit calcium oxalate crystal aggregation and thus could be useful in preventing kidney stone formation [64] (Table 1).

Herbs	Protective effect
Jawarish Zarooni Sada	The formulation was found to decrease the serum urea and serum creatinine levels significantly [21].
Withania somnifera	Significantly reduced toxicity caused by cadmium [32].
Tribulus terrestris	Possess protective effect against the gentamicin induced nephrotoxicity in both structural and functional terms [33].
Banadequl Buzoor	The formulation was found to decrease the serum urea and serum creatinine levels significantly [34].
Quercetin	Produced nephroprotective effect against cisplatin induced nephrotoxicity [35].
Cordyceps sinensis	Protects the proximal tubular cells from gentamicin toxicity [36].
Clerodendron trichotomum	Reported to possess diuretic, natriuretic and kaliuretic activity [37].
Curcumin	reported to produce protective effect against adriamycin induced nephrotoxicity [38].
Ginger	Showed the tubular regeneration potential in animal models [39].
Pomegranate seed oil	Showed attenuation of Diazinon -induced nephrotoxicity [40].
Garlic	Found to be effective in gentamicin induced acute kidney failure [41].
Angelica radix	Demonstrated protective effect against the toxicity [42].
Boerhavia diffusa	Clinically proved to be useful and safe drug in patients of nephritic syndrome [43].
Icacina tricantha	Offered protection against CCL4 induced nephrotoxicity [44].
Echinacea pallida	Showed protective effect against cisplatin nephrotoxicity [45].
Geranium humbergii	Protected abnormality in glomerular epithelial cells [47]

Piper cubeba	Showed significant protective effect against cisplatin and gentamicin induced nephrotoxicity [48,49].
Silybum marianum	Has both hepatic and renal protective effects in rodent models [51].
Picrorhiza kurrooa	Offered protection against various hepatic and renal toxins [55].
Astragalus membranaceus	Effective against experimentally induced glomerulonephritis in rats, especially in reducing proteinuria [57].
Artemisia annua	Improved kidney function as measured by creatinine clearance [58].
Sairei-to, a 12 herb mixture	Shown in human and animal studies to protect the kidney in gentamicin renal toxicity, IgA nephropathy, and lupus nephritis [62].
Salvia miltiorrhiza	Prevented the decline of renal cortical Na-K-ATPase activity induced by ischemia and gentamicin [63].
Herniaria hirsute	Inhibit calcium oxalate crystal aggregation and thus could be useful in preventing kidney stone formation [64].

Table 1: Herbs which are scientifically evaluated for nephroprotective effect

Conclusion

These reports mentioned above are although of preliminary nature and most of them have been carried out on animals models but showing great potential of Traditional Medicine viz Unani, Ayurveda to deliver some promising agents that can be used to treat the kidney diseases or at least, preserve its function and slow its progression. Therefore, the comprehensive clinical trial of Unani diuretics, tonics and nephroprotective drugs gain importance as one of the means of characterizing and identifying a better group of drugs that can be used as actual nephroprotective agent after scientific validation.

References

- Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, et al. (2003) Chronic kidney disease and cardiovascular disease in the Medicare population. *Kidney Int Suppl*: S24-31.
- Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, et al. (2005) Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. *J Am Soc Nephrol* 16: 180-188.
- Lameire N, Jager K, Van Biesen W, De Bacquer D, Vanholder R (2005) Chronic kidney disease: a European perspective. *Nephrol Dial Transplant*, 68: 30-38.
- World Health Organization. Preventing Chronic Disease: A Vital Investment. Geneva; 2005.
- Guildford (1991) Principles and methods for the assessment of nephrotoxicity associated with exposure to chemicals (Environmental health criteria: (EUR; 13222) ISBN 92 4 157119 5 World Health Organization Geneva
- Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, et al. (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. *J Clin Invest* 77: 1925-1930.
- Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, et al. (1993) Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. *J Am Soc Nephrol* 4: 40-49.
- Hannemann J, Baumann K (1990) Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study. *Arch Toxicol* 64: 393-400.

9. Anderson ME, Naganuma A, Meister A (1990) Protection against cisplatin toxicity by administration of glutathione ester. *FASEB J* 4: 3251-3255.
10. Montine TJ, Borch RF (1990) Role of endogenous sulphur containing nucleophiles in an in vitro model of Cisdiammine dichloroplatinum (II) induced nephrotoxicity. *Biochem Pharmacol*, 39: 1751-1757.
11. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. *Cancer* 39: 1357-1361.
12. Shaw SG, Weidmann P, Hodler J, Zimmermann A, Paternostro A (1987) Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. *J Clin Invest* 80: 1232-1237.
13. George Carnuthers S, Hoffman B, Kenneth M, David L, Nieren B W (2000) *Clinical Pharmacology* (4th edn) McGraw-Hill Medical Publishing Division, New Delhi, 79-82.
14. Rafeian-Kopaei M, Baradaran A2, Rafeian M1 (2013) Plants antioxidants: From laboratory to clinic. *J Nephropathol* 2: 152-153.
15. Sharafati R, Sherafati F, Rafeian-kopaei M (2011) Biological characterization of Iranian walnut (*Juglans regia*) leaves. *Turk J Biol*, 35: 635-639.
16. Shirzad H, Taji F, Pourgheysari B, Raisi S, Rafeian-Kopaei M (2012) Comparison of antitumor activities of heated and raw garlic extracts on fibrosarcoma in mice. *J Babol Univ Med Sci*, 14: 77-83.
17. Kazemi S, Asgari S, Moshtaghian J, Rafeian M, Adelnia A, et al. (2010) Liver-protective effects of hydroalcoholic extract of *Allium hirtifolium* Boiss. in rats with alloxan-induced diabetes mellitus. *ARYA Atheroscler* 6: 11-15.
18. Khosravi-Boroujeni H, Mohammadifard N, Sarrafzadegan N, Sajjadi F, Maghroun M, et al. (2012) Potato consumption and cardiovascular disease risk factors among Iranian population. *Int J Food Sci Nutr* 63: 913-920.
19. Shirzad H, Shahrani M, Rafeian-Kopaei M (2009) Comparison of morphine and tramadol effects on phagocytic activity of mice peritoneal phagocytes in vivo. *Int Immunopharmacol* 9: 968-970.
20. Rafeian-Kopaei M, Baradaran A. *Teucrium polium* and kidney. *J Ren Inj Prev* 2013; 2:3-4.
21. Afzal M, Khan NA, Ghufuran A, Iqbal A, Inamuddin M (2004) Diuretic and nephroprotective effect of Jawarish Zarooni Sada--a polyherbal unani formulation. *J Ethnopharmacol* 91: 219-223.
22. Amin KMY, Ahmad S, Khan NA, Antinephrotic syndrome effect of ethno drug Bisehri Booti (*Aerva lanata*) – an experimental study of relevant pharmacological actions, Abstract Book, Fourth International Congress on Ethnobiology, NBRI, Lucknow, 1994: 94.
23. Hamid Nasri, Mahmoud Rafeian-Kopaei (2013) Tubular Kidney Protection by Antioxidants. *Iranian J Publ Health*, 42: 1194-1196
24. Tavafi M (2012) Inhibition of gentamicin-induced renal tubular cell necrosis. *J Nephropathol* 1: 83-86.
25. Rafeian-Kopaei (2012). Medicinal plants and the human needs. *J HerbMed Pharmacol*, 1: 1-2.
26. Tavafi M (2013). Protection of renal tubules against gentamicin induced nephrotoxicity. *J Ren Inj Prev*, 2: 5-6.
27. Shirwaikar A, Issac D, Malini S (2004) Effect of *Aerva lanata* on cisplatin and gentamicin models of acute renal failure. *J Ethnopharmacol* 90: 81-86.
28. Yokozawa T, Suzuki N, Oura H, Nonaka G, Nishioka I (1986) Effect of extracts obtained from rhubarb in rats with chronic renal failure. *Chem Pharm Bull (Tokyo)* 34: 4718-4723.
29. Yokozawa T, Fujioka K, Oura H, Nonaka G, Nishioka I (1991) Effects of rhubarb tannins on uremic toxins. *Nephron* 58: 155-160.
30. Yokozawa T, Fujioka K, Oura H, Tanaka T, Nonaka G, et al. (1995) Confirmation that tannins containing crude drugs have a uraemic decreasing action. *Phytotherapy Research*, 9: 1-5.
31. Naora K, Ding G, Hayashibara M, Katagiri Y, Kano Y, et al. (1992) Pharmacokinetics of [6]-gingerol after intravenous administration in rats with acute renal or hepatic failure. *Chem Pharm Bull (Tokyo)* 40: 1295-1298.
32. Panda S, Gupta P, Kar A (1997) Protective role of Ashwagandha in cadmium induced hepatotoxicity and nephrotoxicity in male mouse. *Current Science*, 72: 546-547.
33. Nagarkatti DS, Rege N, Mittal BV, Uchil DA, Desai NK, et al. (1994) Nephroprotection by *Tribulus terrestris*, Update *Ayurveda-94*, Mumbai 41.
34. Anwar S, Khan NA, Amin KMY, Ahmad G (1999) Effects of Banadiq-Ul-Buzoor in some renal disorders, *Hamdard Medicus*, Vol. XLVII. Hamdard Foundation, Karachi, Pakistan, 4: 31-36.
35. Priya SD, Devi CSS (1999) Preventive effect of Quercetin in cisplatin induced cell injury in rat kidney. *Indian Journal of Pharmacology*, 31: 422-426.
36. Zhen F, Tian J, Li L (1992) Mechanism and therapeutic effect of *Cordyceps sinensis* (CS) on aminoglycoside induced acute renal failure (ARF) in rats. *Chinese Journal of Integrated Traditional and Western Medicine*, 12: 228-291.
37. Lu GW, Miura K, Yukimura T, Yamamoto K (1994) Effects of extract from *Clerodendron trichotomum* on blood pressure and renal function in rats and dogs. *J Ethnopharmacol* 42: 77-82.
38. Venkatesan N, Punithavathi D, Arumugam V (2000) Curcumin prevents adriamycin nephrotoxicity in rats. *Br J Pharmacol* 129: 231-234.
39. HamidNasri, MehdiNematbakhsh, ShaminGhobadi, RoyaAnsari, NajmehShahinfard, et al. (2013) Preventive and Curative Effects of Ginger Extract Against Histopathologic Changes of Gentamicin-Induced Tubular Toxicity in Rats. *Int J Prev Med*, 4: 316-321.
40. Boroushaki MT, Arshadi D2, Jalili-Rasti H2, Asadpour E2, Hosseini A3 (2013) Protective effect of pomegranate seed oil against acute toxicity of diazinon in rat kidney. *Iran J Pharm Res* 12: 821-827.
41. Nasri H, Nematbakhsh M, Rafeian-Kopaei M (2013) Ethanolic extract of garlic for attenuation of gentamicin-induced nephrotoxicity in Wistar rats. *Iran J Kidney Dis* 7: 376-382.
42. Sugiyama K, Ueda H, Suhara Y, Kajima Y, Ichio Y, et al. (1994) Protective effect of sodium L-malate, an active constituent isolated from *Angelica radix*, on cis-diamminedichloroplatinum(II)-induced toxic side effect. *Chem Pharm Bull (Tokyo)* 42: 2565-2568.
43. Singh RH, Udupa KN (1972) Studies on the Indian indigenous drug punarnava (*Boerhaavia diffusa* Linn). Part IV: Preliminary controlled clinical trial in nephritic syndrome. *J. Res. Ind. Med*, 7: 28.
44. Asuzu IU, Abubaker I (1995) The antineoplastic effects of an extract from *Lcacina tricantha*, Journal of herbs, spices and medicinal plants. 3: 9-20.
45. Mustea I, Postescu ID, Tamas M (1997) Experimental evaluation of protective Activity of *Echinacea pallida* against Cisplatin nephrotoxicity "Phytotherapy" research, 11: 263-265.
46. Panday S, Gupta PK (1997) Protective role of Aswagandha in cadmium induced nephrotoxicity in male mouse. *Current Science*, 72: 546-547.
47. Lim BO, Yu BP, Park DK (1998) The inhibitory effects of Ginsenoside and Quercetin on oxidative damage by puromycin aminonucleosides in rats *Phytotherapy Research*, 12: 375-377.
48. Zaid QA, Nasreen Jahan, Ghufuran Ahmad, Tajuddin (2012) Nephroprotective effect of *Kabab chini* (*Piper cubeba*) in gentamycin-induced nephrotoxicity. *Saudi Journal of Kidney Diseases and Transplantation*, 23: 773-781.
49. Zaid Ahmad QA, Ghufuran Ahmad, Tajuddin and M. A. Jafri The study of *Kabab chini* (*Piper cubeba*) for nephroprotective effect in cisplatin induced nephrotoxicity *Unani Medicus* 2010 1(1), 85-91
50. Karimi G, Khoei A, Omidi A, Kalantari M, Babaei J, et al. (2010) Protective effect of aqueous and ethanolic extracts of *P. oleracea* against cisplatin induced nephrotoxicity. *Iranian Journal of Basic Medical Sciences*, 13: 31-35.
51. Combest WL (1998, October). Milk thistle. *US Pharmacist*, 86-94.
52. Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R (1999) Stimulatory effects of silibinin and silicristin from the milk thistle

- Silybum marianum on kidney cells. *J Pharmacol Exp Ther* 290: 1375-1383.
53. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, et al. (1996) Cisplatin nephrotoxicity and protection by silibinin. *Nephrol Dial Transplant* 11: 55-62.
54. Zima T, Kameníková L, Janebová M, Buchar E, Crkovská J, et al. (1998) The effect of silibinin on experimental cyclosporine nephrotoxicity. *Ren Fail* 20: 471-479.
55. Seth P, Kumari R, Madhavan S, Singh AK, Mani H, et al. (2000) Prevention of renal ischemia-reperfusion-induced injury in rats by picroliv. *Biochem Pharmacol* 59: 1315-1322.
56. Rajeshkumar NV, Kuttan R (2003) Modulation of carcinogenic response and antioxidant enzymes of rats administered with 1,2-dimethylhydrazine by Picroliv. *Cancer Lett* 191: 137-143.
57. Su L, Chen YC, Hu JD (2000) Comparisons between different doses of *Astragalus membranaceus* and *Salvia miltiorrhiza* in rats proteinuria. *Chinese Journal of New Drugs and Clinical Remedies*, 19, 205-208.
58. Shi JF, Zhu HW, Zhang C (2002) Therapeutic effect of astragalus on patients with chronic glomerulonephritis. *Acta Medicinalis Secundae Shanghai*, 22: 245-248.
59. Zhu JS, Halpern GM, Jones K (1998) The scientific rediscovery of an ancient Chinese herbal medicine: *Cordyceps sinensis*: Part I. *Journal of Alternative and Complementary Medicine*, 4, 289-303.
60. Lu FM, Lin SY (1989) Effects of FDP and Danshen on renal cortical Na-K-ATPase activity in rats after treatment with renal ischemia and gentamicin. *Chin Med J (Engl)* 102: 516-523.
61. Xu F, Huang JB, Jiang L, Xu J, Mi J (1995) Amelioration of cyclosporin nephrotoxicity by *Cordyceps sinensis* in kidney-transplanted recipients. *Nephrol Dial Transplant* 10: 142-143.
62. Ohno I, Shibasaki T, Nakano H, Matsuda H, Matsumoto H, et al. (1993) Effect of Sairei-to on gentamicin nephrotoxicity in rats. *Arch Toxicol* 67: 145-147.
63. Lu FM, Lin SY (1989) Effects of FDP and Danshen on renal cortical Na-K-ATPase activity in rats after treatment with renal ischemia and gentamicin. *Chin Med J (Engl)* 102: 516-523.
64. Atmani F, Khan SR (2000) Effects of an extract from *Herniaria hirsuta* on calcium oxalate crystallization in vitro. *BJU Int* 85: 621-625.